Screening for Down syndrome using first-trimester ultrasound and second-trimester maternal serum markers in a low-risk population: A prospective longitudinal study

Ultrasound in Obstetrics and Gynecology

Volumn 18, Issue 1, 2001, Pages 26-31

  Audibert, F ^a   Dommergues, M ^a   Benattar, C ^b   Taieb, J ^b   Thalabard, J C ^c   Frydman, R ^c  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Combined risk; Down syndrome; Nuchal translucency; Serum screening

Indexed keywords

ADULT; ARTICLE; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DOWN SYNDROME; FEMALE; FIRST TRIMESTER PREGNANCY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SCREENING TEST; SECOND TRIMESTER PREGNANCY;

BIOLOGICAL MARKERS; CROWN-RUMP LENGTH; DOWN SYNDROME; FEMALE; HUMANS; MASS SCREENING; NECK; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY TRIMESTER, SECOND; PROSPECTIVE STUDIES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0034924844     PISSN: 09607692     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0705.2001.00457.x     Document Type: Article

References (23)

1. Antenatal maternal serum screening for Down's syndrome: Results of a demonstration project
2. Prospective study of prenatal screening for Down's syndrome with free beta human chorionic gonadotrophin
3. Fetal nuchal translucency: Ultrasound screening for chromosomal defects in first trimester of pregnancy
4. Fetal nuchal translucency: Ultrasound screening for fetal trisomy in the first trimester of pregnancy
5. Chromosomal defects and outcome in 1015 fetuses with increased nuchal translucency
6. Screening for fetal trisomies by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation
7. First-trimester ultrasound screening for chromosomal defects
8. Nuchal translucency cannot be used as a screening test for chromosomal abnormalities in the first trimester of pregnancy in a routine ultrasound practice
9. Increased nuchal translucency as a marker for fetal chromosomal defects
10. Effect of first trimester nuchal translucency on second-trimester maternal serum biochemical screening for Down's syndrome
11. The effect of nuchal translucency measurement on second-trimester biochemical screening for Down's syndrome
12. Efficiency of ultrasound and biochemical markers for Down's syndrome risk screening
13. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation
14. Correct estimation of parameters for ultrasound nuchal translucency screening
15. Integrated screening for Down's syndrome based on tests performed during the first and second trimesters
16. First trimester ultrasonograpbic diagnosis of fetal structural abnormalities in a low risk population
17. Screening for Down's syndrome by fetal nuchal translucency measurement in a high-risk population
18. Screening of maternal serum for fetal Down's syndrome in the first trimester
19. Antenatal screening for Down's syndrome
20. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy-associated plasma protein-A
21. Maternal age and gestation specific risk for trisomy 21
22. Role of prenatal ultrasonography in women with positive screen for Down syndrome on the basis of maternal serum markers
23. New Down syndrome screening algorithm: Ultrasonographic biometry and multiple serum markers combined with maternal age